ACTRIMS 2023: Most on Briumvi show no MS activity after 6 months
More than half of the people with relapsing forms of multiple sclerosis (MS) who received Briumvi (ublituximab) in the ULTIMATE clinical trials had no signs of disease activity over the first six months of the trial —…